)
Edge20 Mar 2026
Tetra Pak: The Shape of Innovation
The story of Tetra Pak, the Rausing family, and how a paper tetrahedron gave rise to a company that now delivers almost 180 billion packages a year.
Aptahem
Aptahem (APTA) investor relations material
Aptahem Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary12 Feb, 2026
Executive summary
Fourth quarter marked by strategic progress in clinical development and business positioning, with intensified partner dialogues and increased external interest in the lead candidate Apta-1.
Focus on cost-effective operations with a small, highly skilled team, and strengthened international compatibility.
Aptamer-based therapies are gaining industry traction, supporting the company's differentiated approach.
Financial highlights
Q4 operating income: 829 KSEK (790 KSEK in Q4 2024); full-year: 2,585 KSEK (3,844 KSEK in 2024).
Result after financial items: -1,705 KSEK in Q4 (-2,890 KSEK in Q4 2024); full-year: -6,490 KSEK (-8,606 KSEK in 2024).
Cash and cash equivalents at year-end: 2,964 KSEK (4,132 KSEK in 2024).
Equity ratio at year-end: 98.31% (96.60% in 2024).
Earnings per share: -0.08 SEK in Q4 (-0.23 SEK in Q4 2024); -0.31 SEK for the year (-0.69 SEK in 2024).
Outlook and guidance
Entering 2026 with strong momentum and expectations for a breakthrough year in clinical, business, and strategic terms.
Ongoing need for capital to advance clinical programs and partner discussions; capital raising anticipated within the next twelve months.
Detail US capital raising strategy
What Apta-1 indication is prioritized for Phase 2?
Clarify development cost accounting policy
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Aptahem
- Advanced US listing plans, strengthened IP, and raised 6 MSEK amid ongoing net losses.APTA
Q3 202528 Nov 2025 - Advancing a novel sepsis therapy and preparing for a U.S. listing to unlock growth and partnerships.APTAStatus Update30 Oct 2025
- U.S. listing preparations advance with regulatory, financial, and IP initiatives plus stakeholder updates.APTAStatus Update22 Sep 2025
- Improved financials, strategic partnerships, and U.S. listing plans drive next growth phase.APTAQ2 202528 Aug 2025
- Lower revenue, improved net loss, and new capital support Apta-1's clinical progress.APTAQ3 202413 Jun 2025
- Phase 1 for Apta-1 completed; phase 2 prep, rights issue, and reverse split executed.APTAQ2 202413 Jun 2025
- Q1 2025 saw reduced losses, strategic advances, and a planned rights issue for Aptahem.APTAQ1 20256 Jun 2025
- Net loss narrowed and liquidity improved as Aptahem advanced Apta-1 and secured new partnerships.APTAQ4 20246 Jun 2025
Next Aptahem earnings date
Q1 202628 May, 2026
Aptahem
Next Aptahem earnings date
Q1 202628 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage